Some think that walking the walk trumps talking the talk. We think that both have value. Understanding the vernacular and context—talking the talk—gets discussions on-point faster, and keeps them there. Personal and collective hands-on experience—walking the walk—tempers theory with practicality.
Drawing on over a century of collective experience, the core Back Bay team brings both attributes to each engagement.
Dr. Gertler provides counsel and analysis on franchise and therapeutic-area strategies, and corporate and business development activities. In addition, he advises clients on planning and execution of value-creating transactions across the spectrum of size and stage in the life sciences and medtech. His practice encompasses North American and European public and private commercial-stage and R&D-stage companies from mid to large cap; venture-backed companies; and investment firms focused on the life sciences.
Prior to founding Back Bay, Dr. Gertler served as Senior Partner and Managing Director of Leerink Swann Strategic Advisors, the consulting arm of Leerink Swann. He also led several investment banking groups: BioPharma Investment Banking at Leerink Swann and Health Care Investment Banking at Adams Harkness/Canaccord Adams. In this capacity, he advised on a significant number of equity, partnering and M&A transactions that total multi-billions in aggregate consideration.
From 1998 to 2001, during the latter stages of his full time academic career, Dr. Gertler was also a Venture Partner for Schroder Ventures, now SV Life Sciences. He was part of the Medical Device Investment Team with active involvement in five of the Fund's investments.
In addition, in 1998 he founded CardioVascular Technologies, an endovascular start-up based on one of his inventions in the area of embolic entrapment. In 2000, the company was acquired by Embolic Protection Inc., which was subsequently acquired in 2001 by Boston Scientific.
After training at Columbia University (MD), Yale New Haven Hospital (General Surgery) and the Massachusetts General Hospital (Vascular Surgery), Dr. Gertler was a practicing academic Vascular Surgeon, first as Chief of Vascular Surgery at SUNY-HSCB in New York from 1988 to 2002, and subsequently at the Massachusetts General Hospital (MGH) from 1992 to 2001. He was Associate Professor of Surgery at Harvard Medical School and Co-Director of the Vascular Research and Diagnostic Laboratories at the MGH.
From 1986 to1987, following general surgery training but prior to his vascular fellowship, he served as Instructor in Surgery at Yale Medical School and Director of the Surgical Intensive Care Unit at Yale New Haven Hospital.
Dr. Gertler has published extensively in clinical vascular surgery and endothelial and smooth muscle cell biology. He retains an appointment at both the Health Science and Technology program and the Department of Mechanical Engineering at MIT. He has served as an ad-hoc editor for, among others, the Journal of Vascular Surgery, The New England Journal of Medicine, The Journal of Critical Care Medicine, and Surgery.
He is a frequent lecturer and speaker on strategic issues facing life science companies at all stages and continues to publish in this regard. He currently serves on the external advisory boards of the Petit Institute for Bioengineering at Georgia Tech and the Dean's Advisory Board at Boston University School of Medicine.
Dr. Gertler has a BA from Wesleyan University, an MD from Columbia University College of Physicians and Surgeons, and an MBA in Health Policy and Management from Boston University. He is a Fellow of the American College of Surgeons and a member of numerous academic and clinical surgical societies.
Contact Jonathan P. Gertler, MD: firstname.lastname@example.org
Prior to founding Back Bay, Mr. King was President and Founder of Back Bay Strategies and Kendall Strategies. Both Back Bay and Kendall were international life science consulting practices specializing in product development and commercial strategy, life cycle management and branding. Mr. King and his partners sold Kendall Strategies to WPP Group plc in 1999.
Previously, Mr. King headed the commercial side of MGI Pharma, where he served as Vice President, Business Operations, a corporate officer of this NASDAQ listed company. At MGI, Mr. King acquired the company's initial product portfolio, built an oncology sales and marketing organization and closed numerous R&D partnerships and product acquisition/licensing transactions as he headed the Company's business development team.
At Bain & Company, Mr. King managed project teams working on business unit strategy, acquisitions and divestitures, cost reduction, and competitive strategy for clients in the information services, textile, steel and chemical industries.
At Baxter International, Mr. King helped reposition its plasma derivatives business and launch its total parenteral nutrition product line in Europe.
Mr. King holds an MBA with distinction from the Harvard Business School and an AB with honors in Economics and Chemistry from the University of North Carolina.
Contact Mark A. King: email@example.com
Dr. Leo joined Back Bay from Genzyme, where he led strategic planning projects for the company's $2 billion Personalized Genetic Health (Cerezyme, Fabrazyme, Myozyme), and $500 million Biosurgery (Synvisc, Sepra) business units.
Prior to Genzyme, Dr. Leo was a Director with Leerink Swann's Strategic Advisory group, where he led assignments comprising commercial, R&D, and growth strategies for both big pharma/med-tech and emerging growth clients.
Dr. Leo was also a Principal in Wood Mackenzie's life science consulting practice, and prior to that, was Director of the Belfer Cancer Genomics Center at the Dana Farber Cancer Institute.
Dr. Leo completed his doctorate in Biochemistry and Molecular Pharmacology at the University of Massachusetts Medical School, a post-doctoral fellowship in the Department of Pathology at Harvard Medical School, and his undergraduate degree at Holy Cross College.
Contact Christopher Leo, PhD: firstname.lastname@example.org
With experience formed through functional, operational, and executive leadership roles, Gregg brings a unique focus for generating business results through innovative marketing and branding solutions. He has developed strategies, launches, repositionings, and brand development programs for some of the most successful brands in the world.
Prior to co-founding CatchPoint Partners, Gregg was Managing Director, Head of Marketing and Organizational Development for Leerink Swann, a leading healthcare investment bank. Previously, he was a founding partner at Cambridge BioMarketing Group, where he was instrumental in growing the business from a start-up to one of the largest independent healthcare agencies in the U.S. During that time, Gregg provided strategic leadership and led product launches in multiple categories including infectious disease, cardiovascular, inflammation, auto-immunity, and men's health. He led the launch team for Cubist Pharmaceuticals' novel antibiotic, Cubicin, which became the most successful IV antibiotic launch in US history based on revenues.
Prior to joining Cambridge BioMarketing, Gregg served as VP, Marketing for AMC Entertainment (formerly General Cinema Corporation) where he launched and managed consumer products and services for companies including Coca- Cola, Pepsi-Cola, DreamWorks, and the Walt Disney Company.
Gregg was also responsible for the commercial launch of the first home diagnostic drug test in the US where he gained distribution in over 15,000 drug stores nationwide.
Gregg received a B.A. from Dartmouth College and M.B.A. from The University of North Carolina at Chapel Hill. He sits on the Board of Directors for the Juvenile Diabetes Research Foundation (JDRF) of New England.
Contact Gregg DiPietro: email@example.com
Bob has worked with CEOs and executive teams for Abbott Laboratories, Unilever, American Express, Haemonetics, Humedica, Corning Life Sciences, GE, DuPont, Applied BioSystems, and Johnson & Johnson. As an active participant in all projects, Bob lends his business acumen to clients on important decision-making processes, including vision and value proposition development, brand architecture, brand communications, experience innovation, new product development, brand measurement and cost-effective implementation. He is adept at ensuring that clients have a strong understanding of the interplay between brand, business and culture.
Prior to Back Bay, Bob was a Founding Partner of Protobrand Sciences and served as Chief Operating Officer of BrandEquity International. He has held senior management positions with BBDO Worldwide, and Ogilvy & Mather. Bob is a recipient of the highly coveted Grand EFFIE award for his work on the GE brand campaign "We Bring Good Things To Life."
Bob is an author, lecturer and consultant on brand asset management and integrated communications strategies. Bob has authored articles/ columns on branding that have appeared in publications such as Marketing News, Brand Marketing, Sales and Marketing Magazine and Design Management Institute.
Bob speaks at conferences across the nation on branding and effective communications. He has been a speaker at such well-known organizations as Massport, INC. Magazine's Executive Conference Series, and The Institute for International Research, DMI and numerous other organizations.
Contact Bob Robbins: firstname.lastname@example.org
Dr. Gauldie joined Back Bay from Decision Resources, where he was the Director of Commercial Research focused on the therapeutic and corporate strategies of the leading biopharmaceutical companies.
Prior to that, Dr. Gauldie was a Principal Analyst at Wood Mackenzie with responsibility for the leading US and EU-based pharmaceutical companies and the CNS & Pain therapeutic areas.
In conjunction with GlaxoSmithKline's Neurology and Gastrointestinal CEDD, Dr. Gauldie obtained his doctorate in Neuropharmacology from the University of Edinburgh Medical School, UK, and completed a post-doctoral fellowship in the Department of Pharmacology at the same institution.
Dr. Gauldie also holds undergraduate degrees in Chemistry and Psychology from Queen's University, Canada.
Contact Stephan Gauldie, PhD: email@example.com
Dr. Hoffmann joined Back Bay from Deloitte where she led the Life Sciences arm of Deloitte Research, Deloitte's industry think tank. Dr. Hoffmann was responsible for ideating, researching, and writing fact-based white papers on emerging life sciences industry and the health care trends and drivers. Her papers examined the impact of Accountable Care Organizations, the mobile personal health record, Medical Homes, and social networks in the life sciences and enabled her to serve as an eminent subject matter expert on client engagements and public forums.
Prior to joining Deloitte Research, Dr. Hoffmann was a consultant in the Strategic Advisory group at Leerink Swann, a boutique health care investment bank, where she used her science and technology background to help clients understand how to value and leverage new therapies and technologies. She led projects on a diverse range of topics that include cell therapy opportunities, mapping the diagnostics landscape for colorectal and lung cancer, outlining oncology clinical strategies, determining acquisition opportunities in the next generation sequencing landscape, and helping a start-up platform technology company develop their corporate strategy. Her clients included start ups, mid-cap, and top five biopharma companies.
Dr. Hoffmann holds a PhD in molecular and cell biology from the University of California at Berkeley and a BS in biology from Cornell.
Contact Michelle Hoffmann, PhD: firstname.lastname@example.org
Mr. Kofitsas has more than 10 years' experience in strategy, business development and corporate finance for biotech, pharmaceutical, diagnostic, medical device and healthcare services companies. Mr. Kofitsas has held embedded business development roles with emerging biotech and medical technology companies.
Prior to joining Back Bay Life Science Advisors, Mr. Kofitsas was a Vice President, Healthcare Investment Banking at Oppenheimer & Co., and Senior Associate, Investment Banking at Leerink Swann & Company. While at Leerink Swann, Mr. Kofitsas was part of a team that established the firm's corporate finance/advisory practice.
In his career, Mr. Kofitsas has advised in nearly $2 billion in aggregate deal consideration through strategic (M&A) and financial executions for both private and public life science companies.
Mr. Kofitsas holds a BS degree from Babson College.
Contact Vasilios M. Kofitsas: email@example.com
Ms. Wallace joined Back Bay Life Science Advisors from Back Bay Strategies, an international life science consulting practice specializing in product development and commercial strategy, life cycle management and branding. With years of market research and consulting experience, Ms. Wallace manages all aspects of primary research, including expert recruitment, in-depth interview and focus group moderation, data analysis and presentation.
She has played an essential role in assignments that include product and market assessments, life-cycle strategy, competitive assessments, brand personality development and physician segmentation and targeting.
Ms. Wallace earned a BA from Middlebury College, where she studied French and Pre-Medical Science and graduated magna cum laude. She holds an MBA with honors from Boston University with a focus in Health Sector Management. Fluent in French, Ms. Wallace also brings increased language capacities to the Back Bay team.
Contact Julie P. Wallace: firstname.lastname@example.org
Here are some of the challenges Back Bay has helped our clients meet: